The feasibility of Steady state CBV mapping using ferumoxytol immediately after Gadolinium enhanced MRI of the CNS
OHSU IRB# 17028
This randomized phase II trial studies how well gadolinium and ferumoxytol magnetic resonance imaging (MRI) works in diagnosing patients with abnormalities in the central nervous system. Diagnostic procedures, such as gadolinium and ferumoxytol MRI, may help find and diagnose abnormalities in the central nervous system.
Major eligibility criteria:
- Must have neurological findings or radiological abnormalities in the brain
- Be able to undergo MRI imaging without anesthesia
- No known history of iron overload
- Other eligibility criteria may apply
Currently open at:
Oregon Health & Science University, Portland, Oregon
For more information:
OHSU, Portland Veterans Affairs Medical Center (PVAMC) and the Department of Veterans Affairs have a significant financial interest in Fennec, a company that may have a commercial interest in the results of this research and technology. Dr. Neuwelt, inventor of technology licensed to Fennec, has divested himself of all potential earnings. These potential conflicts of interest were reviewed and managed by the OHSU Integrity Program Oversight Council and the OHSU and PVAMC Conflict of Interest in Research Committees.